Medigus Reaches 10 Patients in Chinese Trial

Medigus (NASDAQ:MDGS) announced there have now been 10 procedures for the MUSE device trial in China.
As quoted in the press release:

“The availability of the MUSE™ procedure in China provides patients with a less invasive option for the long-term treatment of GERD,” said principal investigator, Yunsheng Yang, Director of Gastroenterology Department Clinical center at 301 Hospital and chairman of Chinese Society of Gastroenterology, The General Hospital of People’s Liberation Army in Beijing. “The procedure addresses a new hope and solution between drug therapy and surgical procedures.”
Procedures for the clinical study, which will include approximately 62 patients, have begun at four centers across China:

• The General Hospital of People’s Liberation Army
• Renji Hospital of Shanghai
• Shanghai General Hospital
• Peking University Third Hospital

Procedures are expected to continue through 2017, with results being reported to the CFDA in 2018 as part of the submission for clearance to sell MUSE™ in China.

Click here to read the full press release.

Source: www.marketwired.com